GlassScriptPhysician profile
Gerald P Miletello
NPI 1245217728
$25,844.65
in general payments reported to CMS, 2019-2025
86 companies · $4,088 in 2025
The $4,088 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $3,185 · 2020: $6,224 · 2021: $2,392 · 2022: $3,811 · 2023: $2,884 · 2024: $3,260 · 2025: $4,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,782 · Education: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,781.77 |
| Education | $451.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clinigen, INC. | $5,553.93 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $1,280.02 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,173.39 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $1,122.89 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Veracyte, INC. | $1,017.95 | 2021-2022 | |
| Pfizer INC. | $820.93 | 2019-2025 | |
| Genentech USA, INC. | $805.60 | 2019-2025 | Itovebi, Lunsumio, Phesgo |
| Astrazeneca Pharmaceuticals LP | $763.48 | 2019-2025 | Enhertu, Lynparza, Calquence |
| Janssen Biotech, INC. | $725.75 | 2019-2025 | Tecvayli, Rybrevant, Carvykti |
| Genzyme Corporation | $643.52 | 2019-2025 | |
| Amgen INC. | $567.13 | 2019-2023 | Lumakras, Vectibix, Blincyto |
| Daiichi Sankyo INC. | $524.95 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Gilead Sciences, INC. | $514.12 | 2019-2025 | Trodelvy |
| Lilly USA, LLC | $509.93 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Abbvie INC. | $479.29 | 2019-2025 |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $454.81 | 2019-2025 | Ninlaro, Fruzaqla |
| Sanofi-Aventis U.S. LLC | $444.87 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $395.60 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
| Glaxosmithkline, LLC. | $383.28 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Beigene USA, INC. | $369.63 | 2021-2024 | Brukinsa |
| Exelixis INC. | $364.49 | 2019-2025 | Cabometyx |
| Astellas Pharma US INC | $361.95 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Celgene Corporation | $352.95 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Pharmacyclics LLC, An Abbvie Company | $337.15 | 2019-2023 | Imbruvica |
| Aveo Pharmaceuticals, INC. | $336.56 | 2022-2025 | Fotivda |
| Bayer Healthcare Pharmaceuticals INC. | $328.09 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $303.30 | 2019-2025 | Libtayo, Lynozyfic |
| Incyte Corporation | $284.41 | 2019-2025 | Jakafi, Jakafi |
| Eisai INC. | $259.82 | 2019-2025 | |
| Seagen INC. | $232.08 | 2019-2023 | Tukysa |
| Puma Biotechnology, INC. | $216.67 | 2019-2025 | |
| Sobi, INC | $208.44 | 2023-2025 | |
| Emd Serono, INC. | $207.37 | 2019-2025 | Bavencio |
| Sirtex Medical INC | $205.63 | 2019-2020 | |
| Blueprint Medicines Corporation | $203.56 | 2021-2023 | Ayvakit |
| Karyopharm Therapeutics INC. | $190.39 | 2020-2025 | Xpovio |
| Springworks Therapeutics, INC. | $173.60 | 2024-2025 | Ogsiveo |
| Beone Medicines USA, INC. | $166.65 | 2025 | Brukinsa |
| Morphosys, US INC. | $155.87 | 2021-2023 | Monjuvi |
| Acrotech Biopharma INC. | $148.97 | 2022-2023 | Beleodaq |
| Alexion Pharmaceuticals, INC. | $135.09 | 2019-2022 | |
| Trisalus Life Sciences, INC. | $127.31 | 2023 | Trinav Infusion System |
| Blue Earth Diagnostics | $121.83 | 2019 | |
| Stemline Therapeutics INC. | $116.58 | 2023-2024 | Orserdu |
| Adaptive Biotechnologies Corporation | $102.08 | 2023-2025 | Clonoseq |
| Recordati_rare_diseases_inc. | $97.54 | 2023-2025 | Sylvant |
| Myriad Genetic Laboratories, INC. | $92.85 | 2020-2023 | Precisetumor |
| Pharmacosmos Therapeutics INC. | $88.04 | 2022-2025 | Cosela, Monoferric |
| Novocure INC. | $85.43 | 2024 | Optune |
| Adc Therapeutics America, INC. | $83.02 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $80.88 | 2021-2025 | |
| Kite Pharma, INC. | $70.44 | 2020-2025 | Yescarta |
| Genmab U.S., INC. | $64.89 | 2022-2025 | Epkinly |
| Servier Pharmaceuticals LLC | $61.74 | 2022-2024 | |
| Array Biopharma INC | $59.47 | 2019-2025 | Tukysa, Braftovi, Mektovi |
| G1 Therapeutics, INC. | $57.50 | 2022-2023 | Cosela |
| Pharmaessentia USA Corporation | $50.39 | 2024-2025 | Besremi |
| Janssen Pharmaceuticals, INC | $43.68 | 2019 | |
| Rigel Pharmaceuticals, INC. | $42.98 | 2019 | |
| Clovis Oncology, INC. | $42.58 | 2019-2020 | |
| Mirati Therapeutics, INC. | $40.61 | 2023-2024 | Krazati |
| Spectrum Pharmaceuticals INC. | $40.47 | 2023-2025 | Rolvedon |
| Advanced Accelerator Applications | $40.11 | 2019-2020 | |
| Eusa Pharma (US) LLC | $39.35 | 2019 | |
| Tersera Therapeutics LLC | $38.82 | 2024 | Zoladex |
| Medtronic USA, INC. | $38.59 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $33.22 | 2019 | |
| Kyowa Kirin, INC. | $33.10 | 2021 | |
| Syndax Pharmaceuticals, INC. | $32.82 | 2025 | |
| Agios Pharmaceuticals, INC. | $28.49 | 2019-2020 | |
| Verastem, INC. | $27.12 | 2019-2020 | |
| Sandoz INC. | $25.54 | 2025 | |
| Azurity Pharmaceuticals, INC. | $21.28 | 2024 | Vivimusta |
| Immunocore Limited | $21.16 | 2022 | |
| Acceleron Pharma, INC. | $19.69 | 2021 | |
| Dendreon Pharmaceuticals LLC | $19.13 | 2025 | Provenge |
| Foundation Medicine, INC. | $18.99 | 2023 | |
| Cti Biopharma Corp. | $18.83 | 2022 | |
| Tempus Ai, INC | $18.70 | 2024 | |
| Mylan Institutional INC. | $16.95 | 2019 | |
| Tg Therapeutics, INC. | $16.53 | 2021 | |
| Partner Therapeutics, INC. | $15.93 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $13.62 | 2019 | |
| Secura Bio, INC. | $12.26 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,113.40 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Miletello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.